Tag: Motley Fool

More reading

• Pushpay (ASX:PPH) share price on watch after FY 2021 results
• Is the CSL (ASX:CSL) share price a clear buy?
• 2 excellent ASX dividend shares to buy
• 5 things to watch on the ASX 200 on Wednesday
• 2 buy-rated ASX dividend shares with attractive yields

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Kate O’Brien owns shares of Apple and Rio Tinto Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Alphabet (A shares), Alphabet (C shares), and Apple. The Motley Fool Australia has recommended Alphabet (A shares), Alphabet (C shares), and Apple. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post LIVE COVERAGE: ASX expected to fall; Pushpay reports growth appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2Arppiz

Can the CSL Limited (ASX: CSL) share price be called a clear buy right now? Some of the leading brokers in Australia have had their say.

What’s the latest views on the CSL share price?

Quite a few brokers are positive on the ASX healthcare share giant.

For example, the brokers from Macquarie Group Ltd (ASX: MQG) currently rate the CSL share price as a buy with a price target of $296. That’s only a single digit upside over the next 12 months, but Macquarie is positive on the growing activity at US plasma collection centres. This is an important part of the picture for CSL.

However, Macquarie has pointed out that there are potential competition issues down the road.

Citi is another broker that has a buy rating on CSL shares, with a price target of $310. The broker is also positive on the plasma collection recovery story.

However, not every broker is convinced that the CSL share price is an opportunity today. For example, Morgan Stanley is neutral on CSL with a price target of just $275 – which is where the share price is already trading.

Ord Minnett is also not convinced – its price target is $266.20, which is below where it’s trading now.

What has the CSL share price done recently?

It has been a strange year for CSL so far. It’s actually lower than where it was at the start of the calendar year. But in March the CSL share price went as low as $246, so it has recovered noticeably since then.

CSL recently gave investors a presentation about its current operations and growth plans. In FY21 it’s opening 25 new plasma collection centre, bringing its global network to more than 300. Not only are there 284 centres in the US, but there are also nine in Germany, three in Hungary and five in China. It has plans to open another 40 in FY22.

The healthcare giant has plans to mitigate some of the issues it has seen relating to its plasma collection business. CSL has made adjustments to its US donor compensation. It also has a call back program for first-time, lapsed and temporarily deferred donors. CSL is also doing a large campaign to raise awareness of the opportunity and need for plasma donations.

Looking at the vaccine-focused Seqirus business, CSL has delivered over 100 million doses in the northern hemisphere for its 2020 to 2021 influenza campaign. There’s also an ongoing shift to differentiated products.

In the longer-term, CSL said that planning is underway for the construction of a new cell-culture vaccine facility in Melbourne.

Is it a clear opportunity?

The CSL share price does not offer a lot of upside according to the brokers that rate it as a buy.

At the current CSL share price, it’s valued at around 40x FY21’s estimated earnings.

More reading

• 2 fantastic ASX 50 shares that could be in the buy zone
• ASX 200 Weekly Wrap: Bank shares push ASX 200 towards all-time high
• How shares with massive PE ratios can be cheap
• CSL (ASX:CSL) share price heads lower on haemophilia B deal
• Top brokers name 3 ASX shares to buy today

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Is the CSL (ASX:CSL) share price a clear buy? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/33DTjel

Are you looking for some excellent ASX dividend shares to add to your income portfolio? 

Then you might want to take a look at the ones listed below. Here’s what you need to know about these dividend shares:

National Australia Bank Ltd (ASX: NAB)

If you don’t have exposure to the banks, then you might want to take a look at NAB. Even though its shares have been on fire this year, one leading broker doesn’t believe it is too late to invest.

According to a note out of Goldman Sachs, its analysts have a conviction buy rating and $29.97 price target on the bank’s shares. NAB remains the broker’s preferred sector exposure due to its cost management initiatives, its position as the largest business bank, and its strong capital position.

Goldman is forecasting fully franked dividends of 124 cents per share and 133 cents per share in FY 2021 and FY 2022, respectively. Based on the current NAB share price of $26.81, this will mean yields of 4.6% and 5%.

Sydney Airport Holdings Pty Ltd (ASX: SYD)

Another ASX dividend share to look at is this airport operator. With the domestic tourism market recovering and vaccines rolling out across the world, it may not be long until Sydney Airport’s terminals are packed full of travellers again.

Goldman Sachs is also positive on Sydney Airport and believes it is worth being patient with the company. It notes that the airport remains in an effective hibernation and expects it to be a major beneficiary of the Australian domestic inoculation strategy, if it facilitates relaxation of border restrictions.

The broker currently has a buy rating and $6.73 price target on its shares. It is also forecasting dividends per share of ~8.8 cents and ~27.1 cents over the next two years. 

Based on the current Sydney Airport share price, this will mean yields of 1.4% and 4.3%, respectively.

More reading

• NAB (ASX:NAB) share price lower despite 86 400 acquisition update
• Is the NAB (ASX:NAB) share price great value?
• Commonwealth Bank (ASX:CBA) share price hits record high. Here’s why
• ASX 200 Weekly Wrap: Bank shares push ASX 200 towards all-time high
• The big four banks and Macquarie offer these juicy dividend yields

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 2 excellent ASX dividend shares to buy appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/33ArDH7

On Tuesday the S&P/ASX 200 Index (ASX: XJO) was a very poor performer and sank lower. The benchmark index fell 1.05% to 7,097 points.

Will the market be able to bounce back from this on Wednesday? Here are five things to watch:

ASX 200 expected to fall

It looks set to be another difficult day of trade for the Australian share market on Wednesday. According to the latest SPI futures, the ASX 200 is expected to open the day 39 points or 0.55% lower this morning. This follows a poor night of trade on Wall Street which saw the Dow Jones fall 1.35%, the S&P 500 fall 0.9% and the Nasdaq drop 0.1%. The latter was down as much as 3.5% at one stage before rebounding.

Federal Budget

The Federal Government has just unveiled its “recovery budget” which includes billions of dollars of new funding. Among the biggest winners from the budget will be the aged care sector, which gets a $17.7 billion funding boost, and low to middle income earners. The latter will see up to 10 million Australians receive another tax offset of up to $1,080 in their refunds. This could be a boost to consumer spending.

Oil prices rise

It could be a good day for energy producers such as Santos Ltd (ASX: STO) and Woodside Petroleum Limited (ASX: WPL) on Wednesday after oil prices pushed higher. According to Bloomberg, the WTI crude oil price is up 0.8% to US$65.43 a barrel and the Brent crude oil price has climbed 0.5% to US$68.68 a barrel. Oil prices rose amid fears of fuel shortages in the United States.

Gold price edges higher

Gold miners Evolution Mining Ltd (ASX: EVN) and Newcrest Mining Limited (ASX: NCM) will be on watch after the gold price edged higher overnight. According to CNBC, the spot gold price is up slightly to US$1,838.30 an ounce. Increased demand for safe haven assets was partially offset by rising bond yields.  

Treasury Wine rated as neutral

The Treasury Wine Estates Ltd (ASX: TWE) share price could be fully valued according to analysts at Goldman Sachs. According to a note, ahead of the wine company’s investor day event, the broker has retained its neutral rating and $9.30 price target. It notes that Nielsen data in the US continues to be supportive from a market share perspective. However, the market is now cycling the pandemic driven consumption levels and is subsequently experiencing double digit sales declines in retail.

More reading

• ASX 200 sinks, Boral rises, A2 Milk drops again
• What to expect from the Budget, and a record close for the ASX 200: Motley Fool CIO Scott Phillips on Sky News
• ASX shares that will benefit from the upcoming index changes
• ASX 200 shares hit all-time high! How did we get here?
• This little ASX telco’s picking customers off the big boys: fundie

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Treasury Wine Estates Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 5 things to watch on the ASX 200 on Wednesday appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3feYJBK

Fortunately, in this low interest rate environment, the Australian share market is home to a range of shares that are expected to provide attractive yields to investors in 2021. 

If you’re interested in adding a few to your portfolio, then you may want to look at the ones listed below. Here’s why they could be dividend shares to buy:

Sonic Healthcare Limited (ASX: SHL)

Sonic Healthcare is a leading medical diagnostics company with operations across the world.

It could be a good option due to its strong business model and positive performance during the pandemic.

In respect to the latter, in February Sonic released its half year results and revealed a 33% increase in revenue to $4.4 billion and a massive 166% increase in first half net profit to $678 million.

And while COVID-19 testing has been a key driver of this growth, the rest of the business performed positively as well.

Morgan Stanley is positive on the company. Its analysts currently have an overweight rating and $38.60 price target on its shares.

The broker is also forecasting dividends of 86.2 cents per share in FY 2021 and 89.2 cents per share in FY 2022. Based on the latest Sonic share price of $34.82, this will means yields of 2.5% and 2.6%. 

Wesfarmers Ltd (ASX: WES)

Another option to consider is Wesfarmers. Like Sonic, the conglomerate has been performing very positively in FY 2021.

This has been driven by growth across the majority of its businesses but particularly from the Bunnings business.

The hardware giant has been benefiting from home improvement-related government stimulus and the booming housing market.

Goldman Sachs is also a fan of Wesfarmers and currently has a buy rating and $59.70 price target on its shares. This compares to the latest Wesfarmers share price of $54.81.

The broker is also forecasting fully franked dividends of $1.88 per share in FY 2021 and $1.94 per share in FY 2022. This represents attractive yields of 3.4% and 3.5%, respectively.

More reading

• 2 ASX 200 COVID-19 shares to buy
• ASX 200 Weekly Wrap: Bank shares push ASX 200 towards all-time high
• 2 blue chip ASX dividend shares given buy ratings
• Do brokers think the Wesfarmers (ASX:WES) share price is in the buy zone?
• These ASX dividend shares keep giving investors a payrise

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of Wesfarmers Limited. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 2 buy-rated ASX dividend shares with attractive yields appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3y3RkxF

If you’re looking to boost your portfolio with some quality shares, then you might want to look at the ones listed below.

Here’s why these quality ASX 50 shares have been tipped as ones to buy right now:

CSL Limited (ASX: CSL)

The first ASX 50 share to look at is CSL. It is a biotherapeutics company that manufactures and develops a portfolio of leading therapies and vaccines. Among its portfolio are flu vaccines, immunoglobulins, and a range of other plasma-based products.

While plasma collection headwinds have been weighing on its performance this year, there are signs that conditions are improving rapidly. In fact, last week analysts at Macquarie upgraded the company’s shares to an outperform rating after its research indicated that US plasma collection centre foot traffic has risen materially in recent weeks. Given that the vast majority of CSL’s collection network is in the United States, this bodes well for the future.

As does its burgeoning research and development pipeline which contains a number of potential lucrative products that could be launched in the coming years.

Macquarie currently has a $296.00 price target on the company’s shares. This compares to the latest CSL share price of $274.34.

NEXTDC Ltd (ASX: NXT)

Another ASX 50 share to look at is NEXTDC. It is Australia’s leading data centre operator with a collection of nine world-class centres located across the country. The company is also looking to expand its offering into both the Singapore and Tokyo markets.

The latter expansion would be highly complementary to its Australian business, which continues to go from strength to strength.

For example, during the first half of FY 2021, NEXTDC posted a 27% increase in data centre services revenue to a record $121.6 million and a 29% increase in EBITDA to $65.7 million. This was underpinned by a 33% lift in contracted utilisation to 71MW, a 16% lift in customers, and a 16% rise in interconnections.

Pleasingly, more of the same is expected in the second half. This is thanks to the accelerating shift to the cloud, which has led to very strong demand for capacity in its centres.

Macquarie is also a fan of NEXTDC. It currently has an outperform rating and $13.95 price target on its shares. This compares to the current NEXTDC share price of $10.84.

More reading

• Is the NEXTDC (ASX:NXT) share price in the buy zone?
• ASX 200 Weekly Wrap: Bank shares push ASX 200 towards all-time high
• How shares with massive PE ratios can be cheap
• 2 explosive ASX growth shares rated as buys
• CSL (ASX:CSL) share price heads lower on haemophilia B deal

James Mickleboro owns shares in NEXTDC. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 2 fantastic ASX 50 shares that could be in the buy zone appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3f4yspM

Shares in Mesoblast Limited (ASX: MSB) were once the talk of the ASX, but they’ve been plummeting recently.

The Mesoblast share price has fallen 11.5% since the company’s last announcement on 30 April.

In the April update, Mesoblast released its quarterly results and the results from those aged under 65 involved in its COVID-19 acute respiratory distress syndrome trial.

But it’s what might not have been released that could have investors worried. 

Class action lawsuits against Mesoblast

Last week, the Australian Financial Review (AFR) reported that its attempts to get information from Mesoblast about participants of the trial aged over 65 had been unsuccessful.

It’s likely the company’s silence is not doing much to soothe anxious investors. Particularly, as Mesoblast is no stranger to failing to disclose important information on its drug Remestemcel-L.

As the Motley Fool touched on in October last year, Mesoblast is facing multiple class-action lawsuits in the US. It has been accused of making false or misleading statements to investors and failing to disclose adverse facts about Remestemcel-L.

In addition, an Australian law firm is preparing to engage in a class-action claim against Mesoblast, according to the AFR. The firm states Mesoblast engaged in misleading or deceptive conduct to investors and breaches of disclosure when it promoted Remestemcel-L’s prospects.

The Australian law firm, Phi Finney McDonald, is alleging that Mesoblast misrepresented Remestemcel-L’s effectiveness and potential benefits or the significance of trial results. It also alleges Mesoblast failed to disclose flaws in study design and statistics to the market.

Phi Finney McDonald’s director Tim Finney was quoted by the AFR as saying:

In terms of the potential application for COVID induced ARDS – we intend to allege Mesoblast made claims regarding the success of trials that did not compare apples to apples in terms of clinical outcomes.

We’re yet to hear anything more from Mesoblast, nor anything out of the courts involved in the class actions against Mesoblast.

Mesoblast share price snapshot

The Mesoblast share price has performed poorly on the ASX of late and is down 24% year to date. It’s also fallen 48% over the last 12 months.

The company has a market capitalisation of around $1.1 billion, with approximately 648 million shares outstanding.

More reading

• Why Dubber, Mesoblast, PointsBet, & Sezzle shares are storming higher
• Why the Mesoblast (ASX:MSB) share price is surging 14%

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why does the Mesoblast (ASX:MSB) share price keep falling? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3o86xJv

Do you have some money to invest into ASX dividend shares? There are some wonderful income ideas out there.

There are businesses that are generating both profit growth and paying good dividends. It can be really difficult to find decent yields with growth.

These two ASX dividend shares might be able to offer that attractive combination:

Accent Group Ltd (ASX: AX1)

Accent is the leading Australian shoe retailer. It sells under a number of different brands including 4WORKERS, Hype, Dr Martens, Platypus, Timberland, VANS and Skechers.

The business is growing its sales in a few different ways. It is opening lots of stores – it’s actually aiming to open 90 new stores in FY21. Accent is also growing its like for like store sales, which is driving organic growth, store like for like sales were up 2.7% in the first half of FY21. Online sales have grown particularly strongly over the last year. In HY21, total digital sales increased by 110% to $108.1 million.

It’s this multi-pronged approach that is driving a significant increase of profit for the ASX dividend share.

Accent is benefiting from the strong retail environment, which is allowing it to expand its profit margins. The HY21 gross profit margin increased 140 basis points to 58.1%. Whilst sales only went up 6.6% to $541.3 million, the earnings before interest and tax (EBIT) grew 47.3% to $81.8 million and net profit after tax (NPAT) surged 57.3%.

Profit growth is a big part of what gives boards the confidence to keep increasing the dividend for shareholders. Accent decided to increase the interim dividend by 52.4% to 8 cents per share.

Accent CEO Daniel Agostinelli said:

With long-term objectives and incentives linked to driving at least 10% compound earnings per share (EPS) growth, Accent continues to be defined by strong conversion and the consistently strong returns it delivers on shareholders’ funds.

In other words, Accent wants to be known for paying good dividends. It currently has a grossed-up dividend yield of 6.3%.

Adairs Ltd (ASX: ADH)

Adairs is one of the largest homewares and furniture retailers in Australia and New Zealand.

It’s seeing similar retail trends as Accent. There has been good profit margin improvement, combined with excellent online sales growth. Adairs has revealed that there was a 124% increase in new online customers in the fourth quarter of FY20, compared to the fourth quarter of FY19. FY21 half-year Adairs online sales surged 95.2%.

But Adairs wants to engage with customers on multiple channels. This can lead to customers making purchases more often and spending more on each purchase than customers who only engage through one channel.

The ASX dividend share said that in FY20, the average active member who only shopped online spent $286 and the average active customer who only shopped in store spent $324. Active customers who shopped both in-store and online spent an average of $413 in-store and $318 online, for a total of $731.

The Adairs FY21 half-year result saw group sales increase 34.8%, underlying EBIT rise 166% and statutory net profit grew 233.4%. That translates to EPS of 25.9 cents. This funded an interim dividend of 13 cents per share.

The current trailing Adairs grossed-up dividend yield is 8.1%.

More reading

• Down 9% today, why the Redbubble (ASX:RBL) share price continues to tumble
• 2 highly rated ASX dividend shares with generous fully franked yields
• Got money to invest? Here are 2 ASX shares to buy
• 2 compelling ASX shares to buy in May 2021
• Is there still upside to the JB Hi-Fi (ASX:JBH) share price?

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends ADAIRS FPO. The Motley Fool Australia has recommended ADAIRS FPO and Accent Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Got money to invest for dividends? Here are 2 ASX shares appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/33vJ1wP

The price of the cryptocurrency Ethereum (CRYPTO: ETH) continues to claim headlines. The ‘little sibling’ of Bitcoin (CRYPTO: BTC), Ethereum seems to have picked up the slack from a stagnating Bitcoin price.

While Bitcoin has gone nowhere between February and today (with the usual volatility in between of course), Ethereum has rocketed more than 82% over the same period. In fact, just last night, Ethereum made a new record all-time high of US$4,175 per coin.

But, as is the way of cryptocurrencies, it was not to last. In just the few hours since its new high, the Ethereum price has slid more than 6%, and is going for US$3,894 at the time of writing.

Ethereum rises, then slips

So what’s going on here? The movements of cryptos like Ethereum and Bitcoin can seem like madness and chaos. And we haven’t even mentioned Dogecoin (CRYPTO: DOGE) yet. But perhaps there is at least some method in this madness.

According to eToro’s cryptocurrency analyst Simon Peters, it’s demand from large institutional investors that drove Ethereum’s recent rise:

Demand from institutional investors is fuelling this latest move higher as large-scale buyers diversify their exposure in this emerging asset class, with Ethereum the natural next pick.”

He also cited Ethereum’s lower cost compared to Bitcoin as working in the cryptocurrency’s favour:

This lower dollar value makes Ethereum attractive to investors who want to own whole coins, with the pool of potential investors who could invest $4,000 to buy one ethereum clearly larger than the number of investors who are willing to spend $59,000 to own one Bitcoin.

Peters also points to a recent hard fork of Ethereum, as well as growing numbers of decentralised apps (DApps) as supplementary growth vectors.

Doge days?

Another factor that may be working in Ethereum’s favour is the recent, but dramatic, fall from grace of Dogecoin. The notorious ‘meme coin’, Dogecoin quickly went from a joke over the past few months to be one of the hottest cryptos on the market. That’s what tends to happen when something goes from 7 cents a coin to 70 cents in the space of a month.

But Doge topped out around 72 cents just a few days ago. Since then, Doge has cratered to around 47 cents today, according to CoinDesk.

My Fool colleague Brendon Lau explained why this happened here, but basically, it involves Tesla Inc‘s (NASDAQ: TSLA) Elon Musk and Saturday Night Live (no, I’m not joking). Whilst Doge fell, Ethereum rose to its new highs, so it’s not a stretch to draw a connection there.

More reading

• 3 unstoppable growth trends to invest in today
• 1 simple (and safer) way to invest in cryptocurrency
• Dogecoin price drops by a third after Elon Musk calls it a “hustle” on comedy show
• ASX 200 Weekly Wrap: Bank shares push ASX 200 towards all-time high
• Ethereum breaks new record highs as Bitcoin slips…which one to buy?

Sebastian Bowen owns shares of Bitcoin and Ethereum. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Bitcoin. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Ethereum climbs even higher… but why? Dogecoin might be the answer appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3y44tHi

At the small end of the Australian share market, there are a number of companies with the potential to grow significantly in the future.

Two that investors might want to get better acquainted with are listed below. Here’s what you need to know about them:

Bigtincan Holdings Ltd (ASX: BTH)

The first small cap to watch is Bigtincan. It is a provider of enterprise mobility software to sales and service organisations. This platform allows businesses to increase sales win rates, reduce expenditures, and improve customer satisfaction through improved mobile worker productivity.

Bigtincan has been a positive performer in FY 2021. Management recently advised that is on course achieve the top end of its annualised recurring revenue (ARR) guidance range of $49 million to $53 million this year. This will be a 48% increase on FY 2020’s ARR of $35.8 million.

Morgan Stanley is positive on the company. It currently has an overweight rating and $1.50 price target on its shares. This compares to the latest Bigtincan share price of 82 cents.

Serko Ltd (ASX: SKO)

Another small cap to watch is Serko. It is the online travel booking and expense management provider behind the Zeno Travel corporate travel tool and the Zeno Expense platform.

Given its exposure to travel markets, demand for its offering has fallen heavily during the pandemic. However, with travel markets beginning to recover, Serko has also reported big improvements in its performance. For example, in March it revealed that transaction volumes were averaging 68% of the volumes recorded for the same period in March 2019, which was unaffected by COVID-19.

Looking ahead, a significant deal with travel giant Booking.com could be a game-changer once trading conditions return to normal.

Macquarie is a fan of the company, particularly given its Booking.com deal. It currently has an outperform rating and NZ$7.25 (A$6.72) price target on its shares. This compares to the latest Serko share price of $6.06.

More reading

• Why Beach Energy, Bigtincan, Pointerra, & ResMed are sinking today
• Why the Bigtincan (ASX:BTH) share price is tumbling lower today
• The Tyro Payments (ASX:TYR) share price has gained 30% in 12 months
• 2 exciting small cap ASX shares tipped for big things
• 3 exciting small cap ASX shares for your watchlist

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends BIGTINCAN FPO. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Serko. The Motley Fool Australia has recommended BIGTINCAN FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 2 exciting small cap ASX shares to watch in May appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3eB2uTd